Literature DB >> 2706128

Informing patients about phase I trials--how should it be done?

Y Willems1, C Sessa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2706128     DOI： 10.3109/02841868909111191

Source DB:  PubMed          Journal:  Acta Oncol        ISSN： 0284-186X            Impact factor:   4.089


× No keyword cloud information.
  5 in total

Review 1.  Ethical issues in the development of new agents.

Authors:  C K Daugherty
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

2.  Do Patients With Advanced Cancer Have the Ability to Make Informed Decisions for Participation in Phase I Clinical Trials?

Authors:  Fay J Hlubocky; Greg A Sachs; Eric R Larson; Halla S Nimeiri; David Cella; Kristen E Wroblewski; Mark J Ratain; Jeffery M Peppercorn; Christopher K Daugherty
Journal:  J Clin Oncol       Date:  2018-07-09       Impact factor: 44.544

3.  Investigator Disclosure and Advanced Cancer Patient Understanding of Informed Consent and Prognosis in Phase I Clinical Trials.

Authors:  Fay J Hlubocky; Nancy E Kass; Debra Roter; Susan Larson; Kristen E Wroblewski; Jeremy Sugarman; Christopher K Daugherty
Journal:  J Oncol Pract       Date:  2018-05-22       Impact factor: 3.840

4.  Patients in phase I trials of anti-cancer agents in Japan: motivation, comprehension and expectations.

Authors:  K Itoh; Y Sasaki; H Fujii; T Ohtsu; H Wakita; T Igarashi; K Abe
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

5.  Description of the types and content of phase 1 clinical trial consent conversations in practice.

Authors:  Louisa Wall; Zachary Luke Farmer; Margaret White Webb; Margie D Dixon; Ajay Nooka; Rebecca D Pentz
Journal:  Clin Trials       Date:  2015-08-28       Impact factor: 2.486
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.